Home News

News

FDA Accepts Resubmission of Biologics License Application for Sacituzumab Govitecan

Earlier today the U.S. Food and Drug Administration (FDA) confirmed that it has accepted Immunomedics' Resubmission of the Biologics...

FDA Approves Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-positive Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo and AstraZeneca)*, a HER2 directed...

Novel Treatments are a Positive Development for Patients with Metastatic Urothelial Cancer – But...

This week has brought welcome news to bladder cancer patients and their loved ones. Two drugs with great potential...
Featured Image / Photo courtesy 2019: Cambridge Healthtech Institute (CHI)

Bispecific Antibody Evolution for Cancer Therapy: Advances from Merus, Adimab, Regeneron, F-Star, LAVA Therapeutics...

The concept of using bispecific antibodies for tumor therapy has been developed more than 30 years ago with many...

Accelerated Approval for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer

The U.S. Food and Drug Administration (FDA) granted accelerated approval to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma / Seattle Genetics)*...

Confirmatory Study of Mirvetuximab Soravtansine in Ovarian Cancer on Track to Start by Year-End

In a statement earlier today, ImmunoGen confirmed that the U.S. Food and Drug Administration (FDA) has advised that a...
Speakers and attendees during the morning sessions on Wednesday December 11, 2019. during the San Antonio Breast Cancer Symposium being held at the Henry B. Gonzalez Convention Center in San Antonio, TX. This year is the 42nd Anniversary of the meeting where over 7,500 physicians, researchers, patient advocates and healthcare professionals from over 90 countries attended the meeting which features the latest research on breast cancer treatment and prevention. Photo Courtesy 2019 © MedMeetingImages/Todd Buchanan

SABCS 2019: DESTINY-Breast01 Trial of Trastuzumab Deruxtecan Shows Positive Results in HER2+ Metastatic Breast...

Detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial (NCT03248492) of trastuzumab deruxtecan (DS-8201; fam-trastuzumab deruxtecan in...

ASH 2019: Findings from Phase I Study of IMGN632 Shows Potential in AML and...

New safety and efficacy findings from the dose escalation and expansion of the first-in-human trial of IMGN632 in patients...
Speakers and attendees during Global Capacity Building Showcase at the American Society of Hematology 61th Annual Meeting at the Orange County Convention Center on Sunday December 8, 2019. Photo Courtesy 2019 © ASH/Nick Agro

First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of...

Data from a CD117-ADC, an antibody-drug conjugate being developed by Magenta Therapeutics, were presented at the 61st annual meeting...
General Views during at the American Society of Hematology 61th Annual Meeting at the Orange County Convention Center. Photo courtesey 2019 © ASH/Danny Morton.

ASH 2019: Brentuximab Vedotin + Nivolumab in Frontline and R/R Hodgkin Lymphoma

Updated and long-term follow-up analyses from two clinical trials evaluating brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) and nivolumab (Opdivo®; Bristol‑Myers...